Work

Exploring microbial metabolites in kidney disease: insights into molecular pathways and novel metabolite-targeted therapeutic approaches

Year: 2026
Type: article
Abstract: Chronic kidney disease (CKD) is increasingly recognised as a systemic disorder in which a bidirectional host–microbiota relationship contributes to disease progression. This review is deliberately restricted in scope to the microbial metabolites for which mechanistic and clinical evidence is most developed: the protein-bound uremic solutes indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), and the microbiota-derived co-metabolite trimethylamine N-oxide (TMAO). These harmful metabolites are explicitly contrasted with short-chain fatty acids (SCFAs), the principal class of beneficial microbial metabolites, whose depletion represents a loss of reno-protection rather than a gain of toxicity. In CKD, the colonic milieu is reshaped by urea influx, restricted fruit, vegetable and fibre intake, slowed intestinal transit and repeated antibiotic and phosphate-binder exposure; the resulting dysbiosis favours proteolytic fermentation and the generation of indole and p-cresol, which undergo hepatic and intestinal phase II conjugation to IS and p-CS, while choline- and carnitine-derived trimethylamine is oxidised by hepatic flavin monooxygenase 3 to TMAO. Because these solutes are highly protein-bound, they are poorly cleared by conventional haemodialysis and accumulate as renal function declines. At the molecular level, IS is a well-characterised (AhR), and AhR activation, NADPH-oxidase-derived reactive oxygen species, NF-κB-dependent cytokine transcription and TGF-β1/Smad3-driven matrix deposition together form the best-supported injury cascade; other links, notably metabolite-directed epigenetic remodelling, remain hypothesis-generating. Therapeutic strategies are appraised according to their development stage and the strength of the evidence behind them, from the oral adsorbent AST-120 - whose pivotal EPPIC trials did not meet their primary endpoint - through investigational microbial enzyme inhibitors to experimental AhR antagonists. We argue that the field’s central unmet need is not further descriptive mechanistic work but biomarker-enriched, adequately powered and earlier-initiated clinical trials capable of distinguishing metabolite lowering from clinical benefit.
Language: English
Open Access status: gold
Estimated APC paid: $3,801
Award: G666264997
OpenAlex ID: W7235722530
FWCI:
Cites: 97
Cited by:
Related to: 10